The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Acceleron Pharma Inc. | COM | 00434H108 | 1,686 | 55,767 | SH | SOLE | 55,767 | 0 | 0 | ||
| ACELRX Pharmaceuticals, Inc. | COM | 00444T100 | 4,481 | 816,251 | SH | SOLE | 816,251 | 0 | 0 | ||
| Ambit Biosciences Corporation | COM | 02318X100 | 32,025 | 2,079,569 | SH | SOLE | 2,079,569 | 0 | 0 | ||
| BioDelivery Sciences International, Inc. | COM | 09060J106 | 11,792 | 690,000 | SH | SOLE | 690,000 | 0 | 0 | ||
| Ignyta, Inc. | COM | 451731103 | 4,030 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| Karyopharm Therapeutics Inc. | COM | 48576U106 | 37,635 | 1,077,124 | SH | SOLE | 1,077,124 | 0 | 0 | ||
| Orexigen Therapeutics, Inc. | COM | 686164104 | 5,261 | 1,235,000 | SH | SOLE | 1,235,000 | 0 | 0 | ||
| Xencor, Inc. | COM | 98401F105 | 7,516 | 807,356 | SH | SOLE | 807,356 | 0 | 0 | ||